Hohl Benjamin sold $264K of ELVN
Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $43.80 ($42.78–$44.75, $0.26M total) across 3 trades on 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale totaling ~$263.6K across three trades at ~$42.79–$44.75/share, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity, but a 10b5-1 sale typically carries limited incremental fundamental information.
What to watch
The article provides only the sale details; it does not include any concurrent buy transactions, changes in guidance, or operational/clinical updates that would contextualize the sale.
Background
This is an SEC Form 4 insider transaction disclosure for Enliven Therapeutics, Inc. (ELVN).
Ticker impact
Enliven Therapeutics CFO Hohl Benjamin filed a Form 4 selling $263.6K of ELVN stock under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is an open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, reducing the probability of information leakage.
Market effects
Minimal—this is company-specific insider transaction disclosure, not a sector-wide regulatory/clinical catalyst.
None.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if paired with other negative signals not mentioned here.
Key entities
- issuerEnliven Therapeutics, Inc.
US-listed biotech subject of the Form 4 insider sale disclosure.
- insiderHohl Benjamin
Chief Financial Officer who sold ELVN shares under a pre-arranged 10b5-1 plan.
